BR112013032871B1 - Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154 - Google Patents

Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154 Download PDF

Info

Publication number
BR112013032871B1
BR112013032871B1 BR112013032871-1A BR112013032871A BR112013032871B1 BR 112013032871 B1 BR112013032871 B1 BR 112013032871B1 BR 112013032871 A BR112013032871 A BR 112013032871A BR 112013032871 B1 BR112013032871 B1 BR 112013032871B1
Authority
BR
Brazil
Prior art keywords
antibody
seq
protein
cell
dsbc
Prior art date
Application number
BR112013032871-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013032871A2 (pt
BR112013032871A8 (pt
Inventor
Mark Ellis
David Paul Humphreys
Original Assignee
Ucb Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma S.A. filed Critical Ucb Pharma S.A.
Publication of BR112013032871A2 publication Critical patent/BR112013032871A2/pt
Publication of BR112013032871A8 publication Critical patent/BR112013032871A8/pt
Publication of BR112013032871B1 publication Critical patent/BR112013032871B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112013032871-1A 2011-07-13 2012-07-13 Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154 BR112013032871B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173880 2011-07-13
EP11173880.3 2011-07-13
PCT/EP2012/002945 WO2013007388A1 (en) 2011-07-13 2012-07-13 Bacterial host strain expressing recombinant dsbc

Publications (3)

Publication Number Publication Date
BR112013032871A2 BR112013032871A2 (pt) 2017-01-24
BR112013032871A8 BR112013032871A8 (pt) 2022-08-23
BR112013032871B1 true BR112013032871B1 (pt) 2022-09-27

Family

ID=46545736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032871-1A BR112013032871B1 (pt) 2011-07-13 2012-07-13 Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154

Country Status (27)

Country Link
US (2) US9725516B2 (https=)
EP (2) EP2731973B1 (https=)
JP (3) JP6431370B2 (https=)
KR (1) KR102023786B1 (https=)
CN (1) CN103649124B (https=)
AU (1) AU2012283388B2 (https=)
BR (1) BR112013032871B1 (https=)
CA (1) CA2841824C (https=)
CY (1) CY1119985T1 (https=)
DK (1) DK2731973T3 (https=)
EA (1) EA031449B1 (https=)
ES (1) ES2659155T3 (https=)
HR (1) HRP20180226T1 (https=)
HU (1) HUE035674T2 (https=)
IL (1) IL229947B (https=)
IN (1) IN2014DN00202A (https=)
LT (1) LT2731973T (https=)
ME (1) ME02957B (https=)
MX (1) MX348738B (https=)
NO (1) NO2731973T3 (https=)
PL (1) PL2731973T3 (https=)
PT (1) PT2731973T (https=)
RS (1) RS56926B1 (https=)
SG (1) SG10201807560XA (https=)
SI (1) SI2731973T1 (https=)
SM (1) SMT201800068T1 (https=)
WO (1) WO2013007388A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00832B (me) * 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
US9109216B2 (en) 2009-09-24 2015-08-18 Ucb Pharma, S.A. Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
HRP20180226T1 (hr) * 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
EP3237432B1 (en) 2014-12-22 2023-09-06 UCB Biopharma SRL Protein manufacture
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
CN108495653A (zh) 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
EP3774926A1 (en) 2018-04-05 2021-02-17 Bio-Rad ABD Serotec GmbH Display systems for proteins of interest
EP3877407B1 (en) * 2018-11-05 2026-03-11 F. Hoffmann-La Roche AG Methods of producing two chain proteins in prokaryotic host cells
CN109371049A (zh) * 2018-11-14 2019-02-22 天津大学 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用
EP3942079A1 (en) 2019-03-18 2022-01-26 Bio-Rad ABD Serotec GmbH Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation
DK4010500T3 (da) * 2019-08-05 2025-05-05 Wacker Chemie Ag Bakteriestamme til frigivelse af et rekombinant protein i en fermenteringsfremgangsmåde

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1993022331A1 (en) 1992-04-28 1993-11-11 The Regents Of The University Of Michigan Human crabp-i and crabp-ii
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2000083670A (ja) 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド
DE60031533D1 (de) 1999-06-29 2006-12-07 Siga Technologies Inc Test für degp-protease inhibitoren
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002018446A2 (en) 2000-09-01 2002-03-07 Biogen, Inc. Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins
US7041479B2 (en) 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
WO2002061090A2 (en) * 2000-12-14 2002-08-08 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
JP4056880B2 (ja) 2000-12-14 2008-03-05 ジェネンテック・インコーポレーテッド 細菌性宿主株
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
CN100513414C (zh) * 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
MXPA04004634A (es) 2001-11-16 2004-08-12 Idec Pharma Corp Expresion policistronica de anticuerpos.
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2533593A1 (en) 2003-07-26 2005-02-10 Biogen Idec Ma Inc. Altered antibodies having improved antigen-binding affinity
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
ME00832B (me) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
US7662587B1 (en) 2009-03-05 2010-02-16 E. I. Du Pont De Nemours And Company Gene knockout mutations that increase peptide production
US9109216B2 (en) 2009-09-24 2015-08-18 Ucb Pharma, S.A. Bacterial host strain
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
GB201000591D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
HRP20180226T1 (hr) 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product

Also Published As

Publication number Publication date
PT2731973T (pt) 2018-02-22
WO2013007388A1 (en) 2013-01-17
JP7062626B2 (ja) 2022-05-17
SI2731973T1 (en) 2018-04-30
CA2841824A1 (en) 2013-01-17
ME02957B (me) 2018-07-20
US20170335003A1 (en) 2017-11-23
EP2731973A1 (en) 2014-05-21
CN103649124B (zh) 2016-04-13
IN2014DN00202A (https=) 2015-06-05
HUE035674T2 (en) 2018-05-28
PL2731973T3 (pl) 2018-04-30
LT2731973T (lt) 2018-02-26
EP2731973B1 (en) 2017-11-15
AU2012283388A1 (en) 2014-01-09
KR102023786B1 (ko) 2019-09-20
US20140141468A1 (en) 2014-05-22
NO2731973T3 (https=) 2018-04-14
EA031449B1 (ru) 2019-01-31
RS56926B1 (sr) 2018-05-31
MX348738B (es) 2017-06-27
IL229947B (en) 2019-10-31
CN103649124A (zh) 2014-03-19
JP6431370B2 (ja) 2018-11-28
US9957328B2 (en) 2018-05-01
BR112013032871A2 (pt) 2017-01-24
KR20140039240A (ko) 2014-04-01
AU2012283388B2 (en) 2017-04-20
CY1119985T1 (el) 2018-12-12
SMT201800068T1 (it) 2018-03-08
JP2014521313A (ja) 2014-08-28
HRP20180226T1 (hr) 2018-03-09
JP2018019719A (ja) 2018-02-08
HK1194393A1 (zh) 2014-10-17
CA2841824C (en) 2021-07-13
BR112013032871A8 (pt) 2022-08-23
US9725516B2 (en) 2017-08-08
MX2014000302A (es) 2014-02-17
SG10201807560XA (en) 2018-10-30
JP2020028299A (ja) 2020-02-27
EA201490274A1 (ru) 2014-05-30
EP3339325A1 (en) 2018-06-27
ES2659155T3 (es) 2018-03-14
DK2731973T3 (da) 2018-01-29

Similar Documents

Publication Publication Date Title
JP7062626B2 (ja) 組換えＤｓｂＣを発現する細菌宿主系統
US11261470B2 (en) Recombinant bacterial host cell for protein expression
KR101737152B1 (ko) 돌연변이체 ｓｐｒ 유전자를 포함하고 저하된 ｔｓｐ 활성을 갖는 박테리아 숙주 균주
US9493559B2 (en) Bacterial host strain expressing recombinant DsbC and having reduced Tsp activity
KR101741865B1 (ko) 돌연변이체 ｓｐｒ 유전자 및 야생형 ｔｓｐ 유전자를 포함하는 박테리아 숙주 균주
BR112013000177A2 (pt) processo para purificar proteínas
BR112012006670B1 (pt) Célula bacteriana gram-negativa recombinante, e, método para produzir uma proteína recombinante
HK1194393B (en) Bacterial host strain expressing recombinant dsbc
BR112012016808B1 (pt) Cepa hospedeira bacteriana expressando dsbc recombinante e tendo atividade tsp reduzida
HK40016915A (en) Recombinant bacterial host cell for protein expression
BR112012017425B1 (pt) Cepa hospedeira bacteriana compreendendo um gene spr mutante e tendo atividade tsp reduzida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07K 16/28 , C12N 15/70

Ipc: C12N 1/21 (2006.01), C12N 15/70 (2006.01), C07K 16

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO PARA CORRECAO DO TITULO.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/07/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.